SCHEMBL2482408

SCHEMBL2482408

NC(=O)c1cnc(Cl)cc1NCc1ccc(C(F)(F)F)cc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ASPH Q12797 2/20 0.56
KDM8 Q8N371 2/20 0.56
KDM4E B2RXH2 1/20 0.56
RIOX2 Q8IUF8 1/20 0.56
RPS6KB1 P23443 9/20 0.52
AURKA O14965 8/20 0.52
AURKB Q96GD4 5/20 0.52
JAK3 P52333 2/20 0.48
IRAK4 Q9NWZ3 2/20 0.48
JAK2 O60674 1/20 0.48
JAK1 P23458 1/20 0.48
TYK2 P29597 1/20 0.48
HDAC3 O15379 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
VNN1 O95497 3/20 0.46
CNR1 P21554 1/20 0.44
MAPK8 P45983 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2499437 0.89 RPS6KB1 (0.51) ASPHKDM8KDM4ERIOX2RPS6KB1
SCHEMBL2479832 0.87 RPS6KB1 (0.61) RPS6KB1AURKAAURKBJAK3IRAK4
SCHEMBL2482122 0.86 RPS6KB1 (0.52) KDM4ERPS6KB1AURKAJAK3IRAK4
SCHEMBL2479527 0.86 JAK3 (0.53) KDM4ERPS6KB1JAK3IRAK4JAK2
SCHEMBL2479323 0.85 JAK2 (0.51) ASPHKDM8KDM4ERIOX2RPS6KB1
SCHEMBL12330612 0.85 JAK3 (0.42) ASPHKDM8KDM4ERIOX2RPS6KB1
SCHEMBL12280211 0.85 CDC7 (0.53) KDM4ERPS6KB1JAK3IRAK4JAK2
SCHEMBL12456545 0.85 JAK3 (0.52) KDM4ERPS6KB1AURKAJAK3IRAK4
SCHEMBL12301445 0.84 RPS6KB1 (0.44) ASPHKDM8KDM4ERIOX2RPS6KB1
SCHEMBL2479053 0.84 KDM4E (0.51) KDM4EJAK3IRAK4JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
CN-102227409-A Pyridine-3-carboxyamide derivative KOWA CO 2011-10-26 CN disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE JAK3, JAK1, UACA ASPH 4597/4885KDM8 797/4885KDM4E 1516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.